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HIV epidemic continues to be a severe public health problem and concern within USA and across the globe with about 33 million
people infected with HIV. The frequency of drug abuse among HIV infected patients is rapidly increasing and is another major
issue since injection drug users are at a greater risk of developing HIV associated neurocognitive dysfunctions compared to non-
drug users infected with HIV. Brain is a major target for many of the recreational drugs and HIV. Evidences suggest that opiate
drug abuse is a risk factor in HIV infection, neural dysfunction and progression to AIDS. The information available on the role of
morphine as a cofactor in the neuropathogenesis of HIV is scanty. This review summarizes the results that help in understanding
the role of morphine use in HIV infection and neural dysfunction. Studies show that morphine enhances HIV-1 infection by
suppressing IL-8, downregulating chemokines with reciprocal upregulation of HIV coreceptors. Morphine also activates MAPK
signaling and downregulates cAMP response element-binding protein (CREB). Better understanding on the role of morphine in
HIV infection and mechanisms through which morphine mediates its eﬀects may help in devising novel therapeutic strategies
against HIV-1 infection in opiate using HIV-infected population.
1. Introduction
The HIV epidemic continues to be the most severe public
health problem and concern within USA and across the globe
with about 33 million people infected with HIV. During
the later stages of the disease, HIV-1-infected patients suﬀer
from a wide range of neurological and neurocognitive dis-
orders collectively known as HIV-associated neurocognitive
disorder (HAND) [1–6]). Severe neuropathological changes
resulting in significantly higher neurocognitive dysfunctions
have been linked with other infections or illicit drug abuse.
According to recent studies, it is believed that illicit drug
abuse is one of the leading causes for transmission of HIV
within USA [7–13]. Injection drug users are at a higher
risk of getting infected with HIV and have greater chances
of developing neurological abnormalities and other oppor-
tunistic infections as a result of sharing contaminated needles
and increased risky sexual behavior [14–16]. Combined
HIV infection along with opiate drug addiction has gained
attention in the recent years and is an emerging problem
in the post-HAART era since these individuals live longer;
however, the associated neurological abnormalities remain
among most of the clinical disorders observed in HIV-
infected patients [8–10, 12, 17, 18].
Opioids represent a major class of addictive drugs of
abuse among which heroin is the most abused substance.
Since heroin is converted to morphine in the brain, mor-
phine has been the preferred choice of study [19]. Morphine
has been demonstrated to severely aﬀect the immune
system by modulating the functions of variety of cells like
phagocytes, T cells, and dendritic cells [20–24].
Opioid drugs and HIV viral proteins act in synergy and
thus lead to greater immunosuppression and hence these
drugs are called cofactors for HIV infection. Selective regions
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of the brain such as striatum and hippocampus highly
express opioid receptors and have been associated with
increased viral titers in HIV-infected patients [19, 25, 26].
Apart from modifying the neural response to HIV directly,
opiate drugs also aﬀect the endogenous opioid peptide levels
which in turn modulate the functions of the central nervous
system [19, 25]. Though diﬀerent kinds of opioid receptors
exist, the commonly used opioids such as morphine and
opioid agonists like naloxone bind to the μ opioid receptor
with greatest aﬃnity. This paper summarizes the results from
our and other laboratories supporting the hypothesis that
morphine enhances HIV-1 infectivity and that it aids in the
neuropathogenesis of HAND.
2. Morphine Induces Apoptosis
Chronic abuse of opiate drugs significantly increases the viral
titers and aﬀects the CD4 T cells in HIV-infected subjects
[27, 28]. Apoptosis has been postulated to be a cause for
the significant loss of T cells, thereby worsening the clinical
condition of HIV-infected patients. HIV virus and many
of the proteins that are encoded by HIV genome including
gp120, Tat, Nef, Vpr, Vpu, and HIV protease have been
found to have pro- and/or antiapoptotic qualities [29–32].
Peterson and colleagues have shown that morphine increases
HIV-1 replication in human peripheral blood mononuclear
cells (PBMCs) that are chronically infected with HIV [33,
34]. Our studies for the first time have indicated that
PBMCs treated with morphine induce significant apoptosis
(Figure 1). Cells treated withmorphine showed evident DNA
fragmentation as compared to their respective controls. Our
studies in total suggested that morphine can cause immuno-
suppression during HIV infection possibly by inducing
apoptosis either independently or by acting as a cofactor in
the pathogenesis of HIV infection [35]. In another study,
Moorman et al. [36] reported that freshly isolated human
PBMCs when infected with either HIV-1 gp120/anti-gp120
or morphine (3 μM) alone did not cause a significant apop-
tosis. However, a combined infection withHIV-1 gp120/anti-
gp120 in the presence of morphine significantly enhanced
the percentage of apoptotic cells. Opiate drugs bind to
μ opioid receptors present on diﬀerent kinds of immune
cells and thus aﬀect the inflammatory responses including
macrophage modulation and production of diﬀerent kinds
of cytokines [33, 37, 38]. Upregulation of μ opioid receptor
has been suggested to play an important role inHIV infection
[39]. In correlation with these results, studies of Moorman et
al. have demonstrated that mice lacking μ opioid receptors
showed significantly lowered apoptosis as compared to wild
types when treated with HIV-1 gp120 and morphine [36].
Although morphine primarily exerts its eﬀect by binding
to the μ opioid receptors, it also can bind to other receptors
such as kappa and delta. Studies have shown that treatment
of CD4+ T lymphocytes with synthetic kappa opioid receptor
(KOR) ligands significantly suppressed HIV p24 and CXCR4
expression and such inhibitory action of the KOR ligand
was further shown to be operative in the initial phase of
the virus entry into the cell [40]. In addition, pretreat-
ment of CD4+ lymphocytes with U50,488 inhibited HIV-1
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Figure 1: Morphine induces apoptosis of human PBMCs. PBMCs
were cultured alone or with diﬀerent concentrations of morphine
for 60 h. Total DNA was extracted and electrophoresed on a 1.8%
agarose gel in the presence of ethidium bromide. Arrows indicate
fragmented DNA. Lane A, control culture; lanes B and C, cells
treated withmorphine at concentrations of 10−7 and 10−9M respec-
tively; lane D, cells treated with cortisol at 0.2mg/mL (positive
control); lane M, molecular weight marker. Copyright © 1997,
American Society for Microbiology. This figure is reproduced from
the original article published in Clinical and diagnostic laboratory
immunology, Nair et al. [35].
envelope glycoprotein-mediated membrane fusion in a dose-
dependent manner and such inhibitory activity was blocked
by the KOR antagonist nor-binaltorphimine [41].
Morphine can cross the blood brain barrier (BBB)
causing cerebral dysfunction. Recent studies have demon-
strated that morphine induces apoptosis in human neurons
and such eﬀect was further enhanced in combination
with HIV [42–44]. Further, studies have shown that mor-
phine enhances HIV-Tat-induced toxicity in human neurons
through the opioid receptors by increasing caspase-3 activity
and decreasing BCl2/BAX ratio indicating that the cells
progressed towards apoptosis [42, 44]. Further, addressing
the combined eﬀects of morphine and HIV, Hauser et al.
[42] have demonstrated that Tat alone or morphine alone
resulted in an enhanced immunochemical expression of
the active caspase-3 in young oligodendrocytes in vitro.
However, the expression of caspase-3 was much higher and
additive when exposed to Tat and morphine together and
such upregulation was specifically blocked by the opioid
antagonist naloxone. Further investigations employing the
transgenic mice conditionally expressing HIV-Tat in the
astroglia revealed that Tat and morphine showed additive
eﬀects in oligodendrocytes [42].
P38 MAPK has been shown to be involved in HIV-
induced neuronal apoptosis [45]. The mechanisms involved
in mediating the synergistic eﬀect of HIV and morphine
have also been shown to involve p38 MAPK [43, 45, 46]. In
support of this hypothesis, pretreatment with SB203580, an
inhibitor of MAPK, significantly attenuated the synergistic
eﬀect of HIV viral proteins and morphine. Further, phos-
phorylation of p38 MAPK by either morphine or HIV gp120
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alone was short lived as compared to a combined treatment
with morphine and HIV-1gp120 [43].
3. Morphine Alters the Cytokine Expression in
Human Glial Cells
HIV is known to infect various CNS cells like microglia,
astrocytes and cause neuronal dysfunction leading to demen-
tia. Astrocytes represent a major population of nonneuronal
cells in the brain that comprise about 25–50% of the
total volume of the brain. Several studies have shown
the important role played by astrocytes in supporting the
neurons and their function. Although astrocytes have been
shown to play a vital role in the neuropathogenesis of HIV,
astrocytes are not productively infected with HIV unlike
other cells such as macrophages, microglia, and monocytes.
Morphine is a potential immunosuppressant that crosses
the BBB and regulates immune responses by diﬀerent mech-
anisms in the central nervous system. Neuroinflammation is
a hallmark of HAND associated with changes in chemokine
expression. As said earlier, CNS may be specifically suscep-
tible to synergistic eﬀects of opiate abuse and HIV infection
[47–49]. μ opioid receptor has been shown to be expressed in
astrocytes which may be responsible for the increased eﬀects
of opiate drugs on HIV infection mediated by mechanisms
such as increased calcium and altered cytokine productions
[50]. Astrocytes get activated as a result of the alteration in
the cellular homeostasis thereby leading to the production of
cytokines [51, 52]. IL-8 is one of the first proinflammatory
chemokines that was identified and responds in combination
with other inflammatory factors [53–56]. IL-8 is known to
inhibit the HIV infection by blocking its specific receptor
CXCR2 [57, 58]. Our studies have shown that morphine
at concentrations of 10−7M (P < 0.01), 10−9M, 10−11M
significantly decreased the IL-8 expression in U87 astrocy-
toma cell lines by 29% (P < 0.01), 47% (P < 0.01), and
68% (P < 0.05), respectively (Figure 2), suggesting that
morphine acts as a cofactor for the HIV infection leading
to a significant down-regulation of IL-8 gene expression in a
dose-dependent manner. Similarly, morphine suppressed IL-
8 gene expression in primary astrocyte cultures [47]. Further,
treatment of U87 cell lines and human astrocyte cultures
with morphine for 24 h significantly inhibited the synthesis
and secretion of IL-8 protein [47]. Down regulation of IL-
8 by morphine was completely blocked by the μ receptor
antagonist, β-funaltrexamine suggesting that the suppression
of IL-8 is mediated through this opioid receptor.
Previous studies show that morphine also modulates
the expression of other cytokines such as IL-6, IL-1β, and
TNF-α during HIV infection. [9, 59]. IL-6 and IL-1β,
expression was twice higher in HIV Tat and morphine-
treated BV2 microglial cells (40-fold) as compared to the
Tat-only-treated cells (20-fold). Similarly, TNF-α expression
was at least twofold greater in the HIV Tat- and morphine-
treated cells than those treated with Tat alone suggesting that
morphine exacerbates the cytokine expression. Consistent
with these results Bhokari et al. have reported similar changes
in the cytokine expression associated with primary mouse
microglial cultures [9]. In addition to these cytokines, an
increased expression of IL-12 has been reported in astrocytes
upon HIV and morphine exposure; however the increase
in the IL-12 was not as prominent and as consistent
as the other cytokines [59]. In another study, HIV Tat
has been shown to potentiate the release of neuroactive
cytokines in microglial cells [60]. Studies of El-Hage et
al. [50] have further identified that the combined eﬀects
of HIV and morphine are modulated by the activation of
the transcription factor NF-κB which in turn is mediated
by elevated intracellular calcium levels. Consistent with
these results HIV Tat and morphine together increased
IkBα phosphorylation and induced p65 translocation into
the nucleus. Interestingly, one study has demonstrated that
the cotreatment with morphine significantly inhibited Tat-
induced cytokine production in N9 murine microglial cells
suggesting the immunosuppressive role of morphine [61].
The reason for a decrease in the IL-8 and an increase in other
cytokines like TNF-α, IL-6, and IL-1β is not clear. Detailed
studies may be warranted to delineate these diﬀerential
eﬀects.
4. Morphine Decreases the β-Chemokine
Expression in Astrocytes
Chemokines have taken a central focus in the recent years
mainly due to the fact that they possess inhibitory eﬀects on
HIV infection [62, 63]. Chemokines represent small proteins
of 5–12 kDA in size that are known to act as chemoattractants
for NK cells, T cells, monocytes, neutrophils, fibroblasts,
and endothelial cells. They are important mediators of
transmigration of leucocytes across the BBB and play a
significant role in the neuropathogenesis of HAND since
these molecules recruit and regulate the movement of
inflammatory cells into the CNS. Further, chemokines also
regulate the degree of HIV infection [64, 65]. Deregulation
in chemokine expression is a common phenomenon that is
associated with astrocytes, microglia, macrophages, neurons,
and endothelial cells exposed to virus, viral proteins and
also in HIV dementia patients [66–69]. MIP-1β, also known
as macrophage inflammatory protein has been reported
to block CCR5 and CCR3 receptors [58, 70, 71]. Studies
from our laboratory have shown that astrocytes treated with
morphine at concentrations 10−7M, 10−9M, 10−11M for
a period of 48 h significantly inhibited the protective gene
MIP-1β expression by 78%, 65%, and 43%, respectively [49].
Monocyte chemoattractant protein (MCP)-1 is another
CC-chemokine ligand (CCL2) that is particularly important
in HIV neuropathogenesis in part because it mediates
mononuclear phagocytes and leukocytes migration into the
brain [66, 67]. Lines of evidence have indicated that the
levels of CCL2 (MCP-1) and the CCR2 receptor levels very
well correlate with the neurocognitive defects accompanying
the neuropathogenesis of HIV disease progression [72, 73].
Earlier studies have shown that exposure of astrocytes with
HIV-Tat and morphine together result in a synergistic
increase in the release of the CCL2; however such synergism
was lacking in the microglial cells [59]. Constitutively
expressed CCL2 mRNA was significantly upregulated in
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Figure 2: Morphine inhibits IL-8 gene expression in astrocytes and U87 astrocytoma cells. 3 × 106 cells were cultured and treated with or
without morphine for 24 h. RNA was extracted, reverse-transcribed, and amplified by PCR using primers for IL-8 and housekeeping gene
G3PDH. PCR products were resolved on 1.2% agarose gel by electrophoresis. G3PDH remained unchanged at all periods while morphine
significantly suppressed the expression of IL-8 gene in a dose-dependent manner in U87 astrocytoma (a). Quantitation of the eﬀect of
morphine on IL-8 gene expression by densitometry in U87 cells after normalizing to housekeeping gene (b). Kinetics of morphine inhibition
of IL-8 gene expression in human astrocytes treated with diﬀerent doses of morphine for 24 h (c). Quantitation of the eﬀect of morphine
on IL-8 gene expression in astrocyte cultures by densitometry after normalizing to housekeeping gene (d). This figure is reproduced from
the original article in Journal of Immunology, 169: 3589-99, Mahajan et al. [47]. Morphine regulates gene expression of alpha- and beta-
chemokines and their receptors on astroglial cells via the opioid mu receptor. Copyright 2002. The American Association of Immunologists.
human neurons by morphine exposure in a concentration
and time-dependent manner but not in human astrocytes
andmicroglia cells even thoughmicroglia and astrocytes also
constitutively express CCL2 [74]. A μ opioid receptor agonist
[D-Ala2, N-Me-Phe4, Glyol5] enkephalin (DAMGO) was
shown to increase the expression of proinflammatory
chemokines like CCL2, CCL5, and CXCL10 in PHA-
stimulated human PBMCs at both protein and mRNA
levels [75]. Increased CCL2 in astrocytes near the area of
HIV Tat injection following the systemic administration
of morphine indicates the role of morphine in enhancing
inflammatory responses [48]. Consistent with these reports,
it has been shown that glial activation and inflammation
was attenuated completely in the CCR2 knockout mice
compared to the wild type after the Tat and morphine
injection either alone or together [76]. In addition to CCL2,
CCL5, and CCL3 (MIP-1α) protein and mRNA expression
levels were significantly exacerbated when exposed to Tat
and morphine together as compared to either of them
when present alone. Further these studies indicated that the
ability of morphine to enhance the Tat-induced chemokine
production is mediated by μ opioid receptors [59].
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5. Effect of Morphine on Chemokine Receptors
Infection of cells with HIV requires the presence of core-
ceptors like CCR5, CCR2b, and CCR3 in addition to
CD4+ receptors [58, 70]. These coreceptors are located in
various cell types including brain cells [77]. It is possible
that chemokines bind to more than one specific receptor.
Mip-1β binds to CCR5 and CCR3 while MCP-1 binds to
the CCR2b receptor. Both chemokines and their receptors
have been demonstrated to play important roles in the
neuropathogenesis of HIV infection. These receptors have
also been shown to be present in higher levels in autopsied
brain samples obtained from AIDS patients and have been
shown to act as coreceptors for HIV infection [78–83].
CC-chemokine ligand 5 (CCL5) also known as RANTES
specifically attracts and aids in the migration of the mononu-
clear macrophages and leukocytes to the site of infection
[85]. CCL5 is known to preferentially stimulate an impor-
tant HIV-receptor CCR5. Activation of CCR5 regulates
the pathogenesis of HIV and simian immunodeficiency
virus infection [86–88]. El-Hage et al. [59] have reported
an increase in the CCL5 in HIV Tat-exposed astrocytes.
In addition, morphine increases the CCR5 expression in
astrocytes [49]. Further, the inflammatory and toxic eﬀects
of Tat and morphine together were attenuated in CCL5
null mice [86]. Our studies have demonstrated a dose-
dependent increase in HIV-1 coreceptors CCR2b, CCR3, and
CCR5 in astrocytes treated withmorphine [49] (Figure 3(a)).
Further, the addition of opioid receptor antagonists, nalox-
one β-funaltrexamine, to astrocyte cultures reversed the
morphine-induced eﬀects suggesting that the morphine-
mediated eﬀects were via μ opioid receptor [49]. Mahajan et
al. have also shown that HIV-1 gp120-induced chemokine
receptor expression is exacerbated by morphine in U773
astrocytoma cell lines [84]. Studies by other investigators
have also confirmed the finding that morphine enhances
HIV infection by significantly upregulating CCR5 and such
increase was associated with inhibition of the endogenous
production of beta chemokines in human mononuclear
phagocytes [89]. In addition to these studies, morphine
has been shown to upregulate CCR5 in CD3+ lymphoblasts
and CD14+ monocytes [90]. In another study, Bokhari
and colleagues have demonstrated the upregulation of the
CCR5 in the murine microglia when treated with morphine
and such eﬀect was abolished by treatment with an opioid
receptor antagonist naloxone [9]. Together these studies
indicate that morphine plays a positive role as a cofactor in
the neuropathogenesis of HAND.
6. Signal Transduction Mechanisms That
Mediate-Morphine-Induced Effects in HIV-1
Changes in the expression of chemokines and their receptors
can lead to signaling events that regulate various biological
responses such as increased calcium influx and mitogen-
activated protein kinase (MAPK) activation. Endogenous
opioid peptides and agonists of opioid drugs have the
potential to activate various signaling cascades either by
suppressing adenyl cyclase, cation channels, or MAPK
pathways [91]. Studies from our laboratory have shown
that morphine increases p38 MAPK and down-regulates
cAMP response element binding (CREB) gene and protein
expression in U87 astrocytes [49] (Figures 3(b) and 3(c)).
Consistent with these studies, other investigators have iden-
tified the involvement of various mitogen-activated kinases
in morphine-mediated toxicity [92, 93]. Stimulation of
MAPKs has been shown to regulate the HIV-1 infectivity
[94–96]. Binding of morphine to the μ opioid receptor
stimulates G-protein-associatedmolecules thereby inhibiting
cAMP and resulting in lowered phosphorylation of CREB
[91]. CREB mediated transcription is an important factor
in neuronal adaptive response and has been demonstrated
to be vital for normal neurocognitive functioning [97–
99]. Increased phosphorylation of ERK1/2, JNK, p38, and
Akt in a time-dependent manner has been reported in
human brain microvascular endothelial cells when exposed
to morphine [100]. In another study using human neurons,
Malik et al. showed that the synergistic eﬀects of HIV Tat
and morphine involve JNK and ERK1/2 pathways; however,
there were no changes in the p38 activation [44]. Chronic
treatment of activated T cells with morphine inhibited the
phosphorylation and activation of ERK1/2 and p38 MAPK
further leading to a downregulation of the transcription
factors activator protein-1 (AP-1), nuclear factor of activated
cells (NFAT) and NFκB [101].
Platelet-derived growth factor has been reported to be a
mitogen and chemoattractant for diﬀerent types of cells in
vivo and in vitro and have the ability to induce the production
of cytokines [102–104]. PDGF has been identified to be
expressed at a higher level in the brain of macaques with
SIV encephalitis [105]. Recent reports have demonstrated
that human brain microvascular endothelial cells (HBMECs)
exposed to morphine show increased PDGF mRNA as
well as protein expression, leading to the activation of its
downstream target transcription factor, namely, early growth
response-1(Egr-1) [100]. The activation of both PDGF and
Egr-1 was blocked by using specific inhibitors for ERK,
JNK, and P38 indicating the role of MAP kinases in the
PDGF activation [100]. Further, blockade of the μ opioid
receptor by its antagonist naloxone significantly reduced
the upregulation of both PDGF and Egr-1 suggesting that
these events are mediated through the opioid receptor. The
studies of Wen et al. further show that morphine activates
Akt pathway; however this molecule does not mediate the
activation of either PDGF or Egr-1 [100]. Activation of
PDGF has been reported to be involved in BBB damage.
Down regulation of ZO-1, a tight junction protein by
morphine, has also been reported to be mediated by the μ
opioid receptor and PDGF [106, 107].
7. Conclusions
These studies suggest that the drugs of abuse such as
morphine enhance HIV-1 replication and infectivity in
various cell types such as PBMCs and CNS cells. The
mechanisms involved in such eﬀects may be mediated by
altering HIV-1 coreceptors and chemokines. The ability of
opioids to alter the expression of chemokines and chemokine
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Figure 3: Morphine enhances the expression of CCR2b, CCR5, and CCR3 genes in human astrocytes (a). Astrocyte cultures were treated
with diﬀerent concentrations of morphine for 48 h and the relative expression of the mRNA was determined by real-time PCR. Morphine
significantly upregulated p38 MAPK and downregulated CREB gene (b) and protein expression in astrocytes (c). This figure is reproduced
from Clinical Immunology, 115: 323-32, Mahajan et al. [49, 84]. Morphine modulates chemokine gene regulation in normal human
astrocytes. Copyright 2005, with permission from Elsevier.
receptors by various cells of the central nervous system
may significantly enhance the ability of HIV to infect the
brain. Morphine also alters the status of both pro- and
antiapoptotic molecules finally leading to a higher rate
of apoptosis which is further exacerbated in case of HIV
infection and such events are mediated by various signaling
mechanisms. Overall, HIV infection in the brain may be
enhanced either by viral binding and cellular uptake by
upregulating HIV coreceptors or chemokine expression.
Together, these studies provide important information on
the molecular aspects of morphine, HIV-1 infection, and
HIV pathogenesis, which may help in developing novel anti-
HIV strategies targeting the coreceptors and chemokines.
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